openPR Logo
Press release

Investigation announced for Investors in shares of Elanco Animal Health Incorporated (NYSE: ELAN)

05-13-2020 11:53 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Elanco Animal Health Incorporated (NYSE: ELAN) shares over potential securities laws violations.

An investigation for investors in Elanco Animal Health Incorporated (NYSE: ELAN) shares over potential securities laws violations.

An investigation was announced on behalf of investors of Elanco Animal Health Incorporated (NYSE: ELAN) shares over potential securities laws violations by Elanco Animal Health Incorporated.

Investors who purchased shares of Elanco Animal Health Incorporated (NYSE: ELAN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Elanco Animal Health Incorporated regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Greenfiled, IN based Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for companion and food animals.

Elanco Animal Health Incorporated reported that its annual Total Revenue rose from over $3.066 billion in 2018 to over $3.071 billion in 2019, and that its Net Income declined from $86.5 million in 2018 to $67.9 million in 2019.

On May 7, 2020, Elanco Animal Health Incorporated reported its financial and operating results for the first quarter of 2020. For the quarter, Elanco Animal Health Incorporated reported GAAP earnings per share of -$0.12, missing consensus estimates by $0.18, and revenue of $657.7 million, missing consensus estimates by $62.49 million. Explaining the Company's disappointing results, Elanco Animal Health Incorporated's President and Chief Executive Officer cited, among other factors, "distributor performance" and stated that Elanco Animal Health Incorporated intended "to tighten our approach across many facets of our distributor relationships."

Shares of Elanco Animal Health Incorporated (NYSE: ELAN) closed on May 13, 2020 at $19.29 per share.

Those who purchased shares of Elanco Animal Health Incorporated (NYSE: ELAN) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Elanco Animal Health Incorporated (NYSE: ELAN) here

News-ID: 2044894 • Views: 295

More Releases from Shareholders Foundation

ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) Investor Alert: Deadline in …
A deadline is coming up on September 28, 2020 in the lawsuit filed for certain investors of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) over alleged securities laws violations. Investors who purchased shares of ProShares Ultra Bloomberg Crude Oil (NYSEArca: UCO) have certain options and there are strict and short deadlines running. Deadline: September 28, 2020. NYSEArca: UCO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Long-Term Investors in shares of Forescout Technolog …
An investigation was announced for long-term investors in shares of Forescout Technologies, Inc. (NASDAQ: FSCT) concerning potential breaches of fiduciary duties by certain directors and officers of Forescout Technologies, Inc.. Investors who are current long term investors in Forescout Technologies, Inc. (NASDAQ: FSCT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ:
Investigation announced for Long-Term Investors in shares of Hebron Technology C …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Hebron Technology Co., Ltd.. Investors who are current long term investors in Hebron Technology Co., Ltd. (NASDAQ: HEBT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: HEBT stocks follows a lawsuit filed against Hebron
Investigation announced for Investors in shares of CrossFirst Bankshares, Inc. ( …
An investigation was announced concerning potential securities laws violations by CrossFirst Bankshares, Inc. in connection with certain financial statements. Investors who purchased shares of CrossFirst Bankshares, Inc. (NASDAQ: CFB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether certain statements by CrossFirst Bankshares, Inc. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for Elanco

Pet Pharmaceuticals Market Is Booming Worldwide | Zoetis, Merial, Bayer, Elanco
The pet pharmaceuticals are the medicines used for health maintenance, prevention and cure of diseases of the pets. There is an increase in the population of the pets increasing the demand of pet pharmaceuticals. The pets are facing health problems due to their lifestyle. Hence the pet pharmaceutical market increasing with increasing demand from the market. Advance Market Analytics recently introduced Global Pet Pharmaceuticals Market study with in-depth overview, describing
Global Swine Healthcare Market 2018 -Zoetis, Merck, Merial, Elanco
Accord Market, recently published a detailed market research study focused on the “Swine Healthcare Market” across the global, regional and country level. The report provides 360° analysis of “Swine Healthcare Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Swine Healthcare on the
Newcastle Disease Vaccine Market Forecast to 2017-2022 Kyoto Biken, Elanco, Meri …
Global Newcastle Disease Vaccine Market Research Report 2012-2022 A recent report discusses the market study on "Newcastle Disease Vaccine Market" over the global and major regions, from angles of manufacturers, product types and end industries. This “Newcastle Disease Vaccine Market” research study involved the extensive usage of both primary and secondary data sources, The report on the global Newcastle Disease Vaccine market uses the top-down and bottom-up approaches to define,
Mannanase Market 2017 - American Biosystems, Elanco
Apex Research, recently published a detailed market research study focused on the "Mannanase Market" across the global, regional and country level. The report provides 360° analysis of "Mannanase Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Mannanase industry, and estimates the future trend of Mannanase market on the basis of
GLOBAL TYLOSIN MARKET 2017- HUVEPHARMA, TAIRUI PHARMACEUTICALS, ELANCO, QILU PHA …
The Industry Study on Global Tylosin Market 2017 incorporates the entire aspects of the Tylosin market. This includes extensive analysis, recent industry statistics and upcoming flow of the Tylosin market. The report also describes the size of the Tylosin market, factors controlling Tylosin market growth, various challenges which affect market expansion and economic prominence of the Tylosin market globally. Global Tylosin Market report commences with the overview of the Tylosin Market.
Animal Antibiotics Market 2017- Zoetis Elanco, Merial
MarketReports.biz’s Animal Antibiotics market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market. Request for sample @ https://goo.gl/Su9qUK The report includes the forecasts, Analysis and discussion of important industry trends, market size, market share estimates and